Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Zymeworks Inc. (ZYME)

8.38   -0.54 (-6.05%) 03-22 16:00
Open: 8.92 Pre. Close: 8.92
High: 8.92 Low: 8.36
Volume: 420,681 Market Cap: 537(M)

Technical analysis

as of: 2023-03-22 3:52:46 PM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 10.62     One year: 12.41
Support: Support1: 8.06    Support2: 7.42
Resistance: Resistance1: 9.1    Resistance2: 10.62
Pivot: 8.25
Moving Average: MA(5): 8.51     MA(20): 8.28
MA(100): 8.19     MA(250): 6.89
MACD: MACD(12,26): -0.1     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 80.4     %D(3): 75
RSI: RSI(14): 49.8
52-week: High: 10.8  Low: 4.11
Average Vol(K): 3-Month: 737 (K)  10-Days: 591 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ZYME ] has closed below upper band by 32.4%. Bollinger Bands are 43.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 8.95 - 8.99 8.99 - 9.02
Low: 8.39 - 8.43 8.43 - 8.47
Close: 8.85 - 8.92 8.92 - 8.98

Company Description

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

Headline News

Tue, 21 Mar 2023
Zymeworks (NYSE:ZYME) Receives "Overweight" Rating from Wells ... - MarketBeat

Mon, 20 Mar 2023
Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact - Yahoo Finance

Wed, 15 Mar 2023
Zymeworks Inc. (ZYME) Gains As Market Dips: What You Should Know - Zacks Investment Research

Tue, 14 Mar 2023
Zymeworks to Present Updated Data on Multiple Product ... - Business Wire

Mon, 13 Mar 2023
Analysts Forecast Zymeworks Inc.'s Earnings in the First Quarter of ... - Best Stocks

Thu, 09 Mar 2023
Zymeworks Offers Hope for More than Just Long-Term Investors - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 64 (M)
% Held by Insiders 3.441e+007 (%)
% Held by Institutions 4.9 (%)
Shares Short 7,340 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS 1.3505e+008
EPS Est Next Qtl -0.68
EPS Est This Year -2.99
EPS Est Next Year -2.54
Book Value (p.s.) 0
Profit Margin (%) 30.1
Operating Margin (%) 31.2
Return on Assets (ttm) 15.5
Return on Equity (ttm) 33.5
Qtrly Rev. Growth 1
Gross Profit (p.s.) 1017.14
Sales Per Share 4.53275e+008
EBITDA (p.s.) 2.23934e+008
Qtrly Earnings Growth -4
Operating Cash Flow 0 (M)
Levered Free Cash Flow 144 (M)

Stock Valuations

PE Ratio 0
PEG Ratio -0.5
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0.98

Stock Dividends

Dividend 0
Forward Dividend 7.07e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.